TST-005 is under clinical development by Transcenta and currently in Phase I for Vulvar Cancer. According to GlobalData, Phase I drugs for Vulvar Cancer have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TST-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TST-005 is under development for the treatment of solid tumors including but not limited to non-small cell lung cancer, pancreatic cancer, gastric cancer, biliary tract cancer, small-cell lung cancer, esophageal cancer, nasopharyngeal cancer, HPV associated cancer like cervical cancer, oropharyngeal cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer, rectal cancer and bladder cancer. It is a bi-specific monoclonal antibody acts by targeting PDL1 and TGF beta. It is administered through intravenous route.
Transcenta (Transcenta Holding) that is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. The company is headquartered in Suzhou, Shanghai, China.
For a complete picture of TST-005’s drug-specific PTSR and LoA scores, buy the report here.